Site Editor

Joyce F. Liu, MD, MPH

Advertisement

Advertisement

News

ASCO 2026: Chiauranib Plus Paclitaxel Improves Progression-Free Survival in Platinum-Resistant Ovarian Cancer

News

ASCO 2026: Chemotherapy-Free Combination for Heavily Pretreated Platinum-Resistant Ovarian Cancer

News

ASCO 2026: Short-Term Fasting During Neoadjuvant Chemotherapy May Improve Outcomes in Advanced Ovarian Cancer

Medical Literature

KIF26B Expression Linked to Paclitaxel Resistance and Prognosis in Ovarian Cancer

Medical Literature

Atezolizumab Improves Overall Survival in Late-Relapsing Recurrent Ovarian Cancer

Medical Literature

Mapping Antibody-Drug Conjugate Targets in High-Grade Serous Ovarian Cancer

Medical Literature

Palbociclib Active in CDKN2A-Altered Ovarian Cancer

Bradley J. Monk, MD, on Platinum-Resistant Recurrent Ovarian Cancer: Pembrolizumab Plus Weekly Paclitaxel

Rachel N. Grisham, MD, on Recurrent Low-Grade Serous Ovarian Cancer: Avutometinib/Defactinib

View More

Advertisement

JNCCN Spotlights

Olaparib (Lynparza)

Bevacizumab (Avastin®)

(UPDATE) Niraparib (Zejula)

Trametinib (Mekinist®)—Low-Grade Serous Ovarian Carcinoma

Mirvetuximab Soravtasine-gynx (Elahere)

View More

More

News

BRCA Status May Help Guide Platinum Rechallenge in Ovarian Cancer

ASCO 2026: Chemotherapy-Free Combination for Heavily Pretreated Platinum-Resistant Ovarian Cancer

ASCO 2026: Short-Term Fasting During Neoadjuvant Chemotherapy May Improve Outcomes in Advanced Ovarian Cancer

View More

Advertisement

Published

Medical Literature

Impact of Intraperitoneal Chemotherapy on Survival in Advanced Ovarian Cancer

AACR Special Conference: Questions to Be Answered in Ovarian Cancer Research and Treatment

Paclitaxel Plus Pazopanib in Recurrent Ovarian Cancer

Rucaparib Maintenance Therapy for Platinum-Sensitive Ovarian Cancer

View More

Ongoing

CE Activities

Optimal integration of pembrolizumab into the care of patients with metastatic MSI-high/dMMR gynecologic cancers

Research experience with and ongoing evaluation of anti-PD-1/PD-L1 antibodies in combination with chemotherapy or targeted therapy for advanced ovarian cancer

Addressing Persistent Challenges in Treatment and Management of Low-Grade Serous Ovarian Carcinoma to Amplify the Latest Evidence in Emerging Therapies

Evolution of the Care of Patients With Advanced Ovarian Cancer

View More

Available

Clinical Trials

City of Hope

Fox Chase Cancer Center

Fred Hutchinson Cancer Research Center

Helen Diller Family Comprehensive Cancer Center

View More

Resources

For Your Patients

CancerCare

Foundation for Women's Cancer

American Cancer Society

Rivkin Center for Ovarian Cancer

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2026 National Comprehensive Cancer Network, All Rights Reserved